"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
Descriptor ID |
D011743
|
MeSH Number(s) |
D03.383.742
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1997 | 1 | 0 | 1 |
1998 | 3 | 1 | 4 |
1999 | 0 | 1 | 1 |
2000 | 2 | 0 | 2 |
2001 | 6 | 2 | 8 |
2002 | 18 | 3 | 21 |
2003 | 48 | 12 | 60 |
2004 | 39 | 16 | 55 |
2005 | 30 | 14 | 44 |
2006 | 41 | 17 | 58 |
2007 | 56 | 37 | 93 |
2008 | 53 | 29 | 82 |
2009 | 66 | 23 | 89 |
2010 | 67 | 28 | 95 |
2011 | 55 | 36 | 91 |
2012 | 46 | 39 | 85 |
2013 | 48 | 42 | 90 |
2014 | 38 | 24 | 62 |
2015 | 41 | 37 | 78 |
2016 | 42 | 34 | 76 |
2017 | 43 | 39 | 82 |
2018 | 43 | 37 | 80 |
2019 | 35 | 38 | 73 |
2020 | 23 | 29 | 52 |
2021 | 30 | 22 | 52 |
2022 | 5 | 32 | 37 |
2023 | 2 | 13 | 15 |
2024 | 8 | 1 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 Apr 09; 8(7):1639-1650.
-
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 Mar 26; 8(6):1515-1528.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica. 2024 Feb 01; 109(2):676-681.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. Cell Death Dis. 2024 01 22; 15(1):80.
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.